Literature DB >> 24162739

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

Sam Behjati1,2, Patrick S Tarpey1, Nadège Presneau3,4, Susanne Scheipl3,5, Nischalan Pillay3,6, Peter Van Loo1,7, David C Wedge1, Susanna L Cooke1, Gunes Gundem1, Helen Davies1, Serena Nik-Zainal1, Sancha Martin1, Stuart McLaren1, Victoria Goodie1, Ben Robinson1, Adam Butler1, Jon W Teague1, Dina Halai6, Bhavisha Khatri6, Ola Myklebost8, Daniel Baumhoer9, Gernot Jundt9, Rifat Hamoudi3,4, Roberto Tirabosco6, M Fernanda Amary6, P Andrew Futreal1, Michael R Stratton1, Peter J Campbell1,10,11, Adrienne M Flanagan3,4,6.   

Abstract

It is recognized that some mutated cancer genes contribute to the development of many cancer types, whereas others are cancer type specific. For genes that are mutated in multiple cancer classes, mutations are usually similar in the different affected cancer types. Here, however, we report exquisite tumor type specificity for different histone H3.3 driver alterations. In 73 of 77 cases of chondroblastoma (95%), we found p.Lys36Met alterations predominantly encoded in H3F3B, which is one of two genes for histone H3.3. In contrast, in 92% (49/53) of giant cell tumors of bone, we found histone H3.3 alterations exclusively in H3F3A, leading to p.Gly34Trp or, in one case, p.Gly34Leu alterations. The mutations were restricted to the stromal cell population and were not detected in osteoclasts or their precursors. In the context of previously reported H3F3A mutations encoding p.Lys27Met and p.Gly34Arg or p.Gly34Val alterations in childhood brain tumors, a remarkable picture of tumor type specificity for histone H3.3 driver alterations emerges, indicating that histone H3.3 residues, mutations and genes have distinct functions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24162739      PMCID: PMC3839851          DOI: 10.1038/ng.2814

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  26 in total

1.  Differential expression of human replacement and cell cycle dependent H3 histone genes.

Authors:  Derk Frank; Detlef Doenecke; Werner Albig
Journal:  Gene       Date:  2003-07-17       Impact factor: 3.688

2.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

3.  Developmental expression of H3.3A variant histone mRNA in mouse.

Authors:  L A López-Fernández; D M López-Alañón; V Castañeda; D B Krimer; J del Mazo
Journal:  Int J Dev Biol       Date:  1997-10       Impact factor: 2.203

4.  Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.

Authors:  M A Horton; M L Taylor; T R Arnett; M H Helfrich
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

5.  CD14- mononuclear stromal cells support (CD14+) monocyte-osteoclast differentiation in aneurysmal bone cyst.

Authors:  Richard Mi Taylor; Takeshi G Kashima; Francesca K E Hemingway; Arundhati Dongre; Helen J Knowles; Nicholas A Athanasou
Journal:  Lab Invest       Date:  2012-02-13       Impact factor: 5.662

6.  Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens.

Authors:  M A Horton; D Lewis; K McNulty; J A Pringle; T J Chambers
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

7.  H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?

Authors:  Marco Gessi; Gerrit H Gielen; Jennifer Hammes; Evelyn Dörner; Anja Zur Mühlen; Andreas Waha; Torsten Pietsch
Journal:  J Neurooncol       Date:  2013-01-26       Impact factor: 4.130

8.  The human replacement histone H3.3B gene (H3F3B).

Authors:  W Albig; B Bramlage; K Gruber; H G Klobeck; J Kunz; D Doenecke
Journal:  Genomics       Date:  1995-11-20       Impact factor: 5.736

9.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

10.  P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers.

Authors:  T Lasky; E Silbergeld
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

View more
  255 in total

Review 1.  [Avoiding pitfalls in the diagnostics of bone neoplasms: importance of reference pathology].

Authors:  M Werner
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  [Minutes of the meeting of the working group on bone, joint and soft tissue pathology: Congress of the German Society of Pathology on 31 May 2015].

Authors:  S Scheil-Bertram; V Krenn; K Hauptmann
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 3.  Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications.

Authors:  Adrian Marino-Enriquez
Journal:  Surg Pathol Clin       Date:  2015-09

4.  Giant cell tumor of soft tissue is genetically distinct from its bone counterpart.

Authors:  Jen-Chieh Lee; Cher-Wei Liang; Christopher Dm Fletcher
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

5.  Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.

Authors:  Yupeng Zheng; Luca Fornelli; Philip D Compton; Seema Sharma; Jesse Canterbury; Christopher Mullen; Vlad Zabrouskov; Ryan T Fellers; Paul M Thomas; Jonathan D Licht; Michael W Senko; Neil L Kelleher
Journal:  Mol Cell Proteomics       Date:  2015-08-13       Impact factor: 5.911

6.  Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.

Authors:  Ahmad Al-Sukaini; Francis J Hornicek; Zachary S Peacock; Leonard B Kaban; Soldano Ferrone; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2017-07-19       Impact factor: 4.176

7.  Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.

Authors:  Inga-Marie Schaefer; Jonathan A Fletcher; G Petur Nielsen; Angela R Shih; Marco L Ferrone; Jason L Hornick; Xiaohua Qian
Journal:  Cancer Cytopathol       Date:  2018-05-14       Impact factor: 5.284

8.  Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.

Authors:  Kartik N Rajagopalan; Xiao Chen; Daniel N Weinberg; Haifen Chen; Jacek Majewski; C David Allis; Chao Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

9.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

Review 10.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.